Saturday, 31 October 2026European Markets

PIERRE VACANCES Stock Is 34% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of pierre vacances (cac 40: vac.pa) rose by a staggering 34.86% in 21 sessions from €1.27 to €1.71 at 16:07 est on wednesday, after two consecutive sessions in a row of gains. cac 40 is jumping 0.95% to €7,282.40, after two consecutive sessions in a row of gains.

pierre vacances's last close was €1.78, 75.95% below its 52-week high of €7.40.

about pierre vacances

pierre et vacances sa, through its subsidiaries, engages in the holiday accommodation and holiday property investment business in europe and internationally. the company operates through two segments, property development and tourism. it engages in the property development and; operation of residences and villages marketed under the pierre & vacances, center parcs, maeva, and aparthotels adagio brands. the company also offers online holiday rental and rental management services through its platform maeva.com. it operates approximately 283 sites and 44,500 apartments. the company was founded in 1967 and is headquartered in paris, france. pierre et vacances sa is a subsidiary of société d'investissement touristique et immobilier.

earnings per share

as for profitability, pierre vacances has a trailing twelve months eps of €9.93.

pe ratio

pierre vacances has a trailing twelve months price to earnings ratio of 0.17. meaning, the purchaser of the share is investing €0.17 for every euro of annual earnings.

more news about pierre vacances (vac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com